Is Telix Pharmaceuticals Limited (TLX) a Buy, Sell, or Hold?
Telix Pharmaceuticals Limited
NASDAQ:TLX
$11.29 USD
$0.27 (2.45%)
- Volume
- 56.58K
- Average Volume
- 185.39K
- Market Capitalization
- $3.82B
- P/E Ratio
- -486.29
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $16.94
- Year Low
- $6.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.43
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Christian Behrenbruch |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TLX |
| CUSIP | 87961M105 |
| CIK | 0002007191 |
| Web | https://telixpharma.com |
| Phone | 61 3 9093 3855 |
| Currency | USD |
| Employees | 1136 |
| Country | AU |
Liquidity
| Debt-to-Equity Ratio | 1.12 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.43 |
| Quick Ratio | 1.27 |
| Cash Ratio | 0.61 |
Sales & Book Value
| Annual Sales | $1.21B |
| Price / Sales | 4.32 |
| Cash Flow | -0.23 |
| Price / Cash Flow | -68.09 |
| Price / Book | 8.49 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $17.00 |
| Forecast Upside/Downside | -43.55% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.0316 |
| Trailing P/E Ratio | -486.29 |
| PEG Ratio | 4.01 |
| P/E Growth | 4.01 |
| Net Income | $-10.69M |
| Net Margin | -0.89% |
| Pretax Margin | -0.65% |
| Return on Equity | -1.72% |
| Return on Assets | -0.61% |
Financials Score
| AltmanZ Score | 4.08 |
| Piotroski Score | 3.00 |
| Working Capital | 147.8M |
| Total Assets | 1.77B |
| Ebit | 124.36M |
| Market Cap | 5.37B |
| Total Liabilities | 1.15B |
Poll Results
About Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The com ... pany is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
2026-07-15 16:20:00
MELBOURNE, Australia and INDIANAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and St Vincent's Hospital today announced that the first patients have been dosed with TLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) in the OPTIMAL-e trial, led by Professor Louise Emmett for patients with metastatic hormone-sensitive prostate cancer (mHSPC) at St Vincent's Hospital in Sydney, Australia.
FDA Alignment to Advance ProstACT Global Phase 3 Trial
2026-07-01 21:31:00
MELBOURNE, Australia and INDIANAPOLIS, July 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, “Telix”) today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial of its therapeutic candidate TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in metastatic castration resistant prostate cancer.
2026-06-30 01:32:09
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript
2026-06-22 17:40:00
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these.
Telix and United Imaging Announce Strategic Theranostics Collaboration
2026-06-02 07:00:00
MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing integrated theranostics solutions.
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
2026-06-01 17:00:00
MELBOURNE, Australia and INDIANAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces the oral presentation of Part 1 safety, dosimetry and pharmacokinetics data from the ProstACT Global Phase 3 Study of TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), in metastatic castration-resistant prostate cancer (mCRPC). The late-breaking data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois by study Principal Investigator Pedro C. Barata, MD, Medical Oncologist, University Hospitals Seidman Cancer Center and Associate Professor of Medicine, Case Western Reserve University of School of Medicine, Cleveland, Ohio.
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
2026-05-27 07:00:00
MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46th Annual Growth Stock Conference in Chicago, IL and in the Jefferies Global Healthcare Conference in New York, NY.
Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up
2026-05-18 18:43:16
Telix Pharmaceuticals Limited offers a potent mix of derisking, downside cushion, and accelerating clinical/commercial momentum in the radiopharmaceutical and diagnostic space. TLX reported Q1 revenue of $230M (up 11% QoQ), reaffirmed FY26 guidance of $950M–$970M, and expects further upside from new diagnostic approvals. Strategic collaborations (notably with Regeneron) and high-profile board appointments reinforce TLX's growth trajectory and potential acquisition appeal.
Frequently Asked Questions
-
What is the current Telix Pharmaceuticals Limited (TLX) stock price?
-
Telix Pharmaceuticals Limited(NASDAQ:TLX) stock price is $11.29 in the last trading session. During the trading session, TLX stock reached the peak price of $16.94 while $6.28 was the lowest point it dropped to. The percentage change in TLX stock occurred in the recent session was 2.45% while the dollar amount for the price change in TLX stock was $0.27.
-
TLX's industry and sector of operation?
-
The NASDAQ listed TLX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TLX?
-
Christian Behrenbruch GAICD | Co-Founder, MD, Group Chief Executive Officer & Executive Director
David N. Cade MBBS | Group Chief Medical Officer
Christian Krautkramer | Group General Counsel
Craig Ulrick | Chief Information Officer
Darren Patti | Group Chief Operating Officer -
How many employees does TLX have?
-
Number of TLX employees currently stands at 1136. TLX operates from 55 Flemington Road, North Melbourne, VIC 3051, AU.
-
Link for TLX official website?
-
Official Website of TLX is: https://telixpharma.com
-
How do I contact TLX?
-
TLX could be contacted at phone #61 3 9093 3855 and can also be accessed through its website. TLX operates from 55 Flemington Road, North Melbourne, VIC 3051, AU.
-
How many shares of TLX are traded daily?
-
The average number of TLX shares traded daily for last 3 months was 185.39K.
-
What is the market cap of TLX currently?
-
The market value of TLX currently stands at $3.82B with its latest stock price at $11.29